Literature DB >> 2295068

Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.

E R Lilley1, M C Rosenberg, G B Elion, O M Colvin, D D Bigner, H S Friedman.   

Abstract

Based on previous work demonstrating the activity of cyclophosphamide and melphalan in a series of human medulloblastoma and rhabdomyosarcoma cell lines and transplantable xenografts, investigations were conducted to define the effects of combining cyclophosphamide or melphalan with VP-16. These studies demonstrated a synergistic interaction between cyclophosphamide and VP-16 and melphalan and VP-16 in the treatment of the human rhabdomyosarcoma cell line TE-671 growing in athymic mice. The combination of cyclophosphamide or melphalan with VP-16 may warrant consideration as a therapeutic strategy for solid tumors sensitive to bifunctional alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295068

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

Review 1.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors.

Authors:  David S Ziegler; Richard J Cohn; Geoffrey McCowage; Frank Alvaro; Cecilia Oswald; Robert Mrongovius; Les White
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

3.  Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.

Authors:  Antonio Ruggiero; Daniela Rizzo; Giorgio Attinà; Ilaria Lazzareschi; Palma Maurizi; Vita Ridola; Stefano Mastrangelo; Roberta Migliorati; Patrizia Bertolini; Cesare Colosimo; Riccardo Riccardi
Journal:  J Neurooncol       Date:  2013-05-12       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.